Send to

Choose Destination
Front Oncol. 2019 Feb 26;9:106. doi: 10.3389/fonc.2019.00106. eCollection 2019.

Everolimus in Anaplastic Thyroid Cancer: A Case Series.

Author information

Dana-Farber Cancer Institute, Boston, MA, United States.
Miami Cancer Institute, Miami, FL, United States.
Brigham and Women's Hospital, Boston, MA, United States.
Yale School of Medicine, New Haven, CT, United States.
Icahn School of Medicine at Mount Sinai, New York, NY, United States.


Background: Anaplastic thyroid cancer (ATC) is a very aggressive disease and accounts for over 50% of thyroid-cancer related deaths. mTOR inhibition has shown anti-tumor activity in ATC. We report our experience treating patients with ATC with everolimus off-protocol. Methods: Patients with confirmed ATC and treated with everolimus at DFCI were identified and reviewed retrospectively. NexGen sequencing was performed, and radiologic responses were correlated with mutational profile. Results: Five patients were treated from 2013 to 2016. Three patients had a response, which included one patient who achieved a partial response for 27.9 months, and two patients who had stable disease for 3.7 and 5.9 months, respectively. Genomic analysis was available in two patients and revealed that the partial responder had mutations involving the PI3K/mTOR pathway. Conclusion: Everolimus has anti-tumor activity in ATC, and responses may correlate with mutations involving the PI3K/mTOR pathway. Further studies are warranted.


PI3K mTOR; anaplastic thyroid cancer (ATC); exceptional responder; mTOR inhibition in head and neck cancer; precision medicine

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center